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The mechanism of fever in patients with Hodgkin's disease was investigated
by examining endogenous pyrogen production by blood, spleen, and lymph node
cells incubated ini vitro. Blood leucocytes from febrile or afebrile patients with
Hodgkin's disease did not produce pyrogen spontaneously. Spleen cells, however,
frequently released pyrogen during initial incubations, unlike spleen cells from pa-
tients with non-malignant diseases. Pyrogen production occurred from spleens withoit
observed pathologic infiltrates of Hodgkin's disease. Lymph nodes involved with
Hodgkin's disease produced pyrogen more frequently than did nodes involved with
other diseases. Pyrogen production by tissue cells was prolonged, required protein
synthesis, and in some cases was dLte to mononuclear cells; it did not correlate
with fever in the patient. These studies demonstrate spontaneous production of
endogenous pyrogen in vitro by lymphoid tissue cells from patients with Hodgkin's
disease.
Although fever occurs commonly in Hodgkin's disease (1, 2), its cause is un-
known. In animal models, the pathogenesis of fever due to infection and hypersensi-
tivity has been clearly related to production of endogenous pyrogen by blood or
tissue leucocytes following stimulation by microbial or antigenic agents (3). Only
phagocytic cells, including granulocytes, monocytes, and macrophages appear to
produce pyrogen. After being released into the blood, this small protein apparently
causes certain hypothalamic neurons to initiate mechanisms for heat production
and conservation, resulting in fever. In man, although similar mechanisms have
been postulated to explain clinical fevers, experimental support for such events
is lacking.
This report describes the production of endogenous pyrogen in vitro by blood
and lymphoid tissue cells from patients with Hodgkin's disease. The results demon-
' Supported by a grant (A1-01564-15) from the United States Public Health Service.
2 A preliminary report was presented to the American Society for Clinical Investigation,
Atlantic City, New Jersey May 1972.
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strate that lymphoid tissue cells, but not blood cells, from these patients often spon-
taneously produce pyrogen during in vitro incubations. In contrast, lymphoid tis-
sues of patients with nonmalignant diseases produce little or no pyrogen under the
same conditions.
MATERIALS AND METHODS
All glassware, solutions, and instruments were rendered sterile and pyrogen-free,
using methods described previously (4). Samples of all specimens obtained from
patients, as well as all supernatants to be injected into rabbits, were cultured in
thioglycollate broth. Supernatants from experiments where bacterial contamination
occurred were discarded.
Pyrogeni Testing
Pyrogen testing was carried out in rabbits, as described previously (4-6). Auto-
matic temperature recording equipment (Rustrak) was used in most experiments.
Between 1 and 6 rabbits received samples of a single supernatant for testing, de-
pending on the amount of material available. Whenever possible, the same rabbits
received samples of supernatant from all experimental flasks in an experiment. A
positive response was judged to be an average temperature elevation of >0.30C,
when the maximum rise occurred between 30 and 75 min after injection of the
test material. In this assay, the height of responses between 0.3 and 0.70C AT
were considered proportional to the quantity of pyrogen present in the sample (7,
8).
Blood Leucocvtes
Blood leucocyte suspensions were prepared from heparinized venous blood (10
units/ml). Red blood cells were removed by natural sedimentation, or by addition
of dextran as described previously (4), except that hypotonic lysis was omitted.
After centrifugation of the leucocyte-rich supernatant at 600g for 15 min, the
cells were suspended in modified Krebs-Ringer Phosphate (KRP) buffer (4), or
tissue culture medium with heparin, penicillin, and streptomycin (Eagle's Minimum
Essential Medium, Auto-POW, Flow Laboratories, Inc., Rockville, Maryland)
(MEM). After determination of leucocyte count with a Coulter counter, cells were
added to flasks with 10-15% autologous plasma or serum, to a concentration of
6-10 X 106 cells/ml. Heat-killed Staphylococcuts albus (4), was added to some
flasks as a phagocytic stimulus. After 18 hr incubation at 370C, supernatants were
recovered, stored, and tested for pyrogen. Usually each rabbit received supernatant
from 3 to 5 X 107 leucocytes; in some experiments with blood leucocytes from
febrile patients, doses were increased to 2 X 10`.
Tissue Cells
Sterile portions of spleens or lymph nodes obtained at operation were weighed,
suspended in cold MEM, and then minced with fine scissors, or forced through
wire gauze to prepare a tissue cell suspension. Leucocyte counts, differential smears
for Wright's and Giemsa stain, and cultures were then taken, and the suspensions
divided into aliquots for incubation according to wet weights. For spleens, approxi-
mately 1 g of tissue was suspended in a 5 ml volume, and for lymph nodes, 100-200
mg 10-15% autologous serum, or rarely, normal donor 0 negative serum was added
to all incubation flasks. Heat-killed staphylococci were usually added to one flask.
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The flasks were saturated with 5% CO2 in air, sealed with parafilm over cotton
plugs, and incubated with slow shaking on a Dubnoff or Egerbach incubator at
370C overnight. The suspensions were then recovered by centrifugation at 600g for
15 min, and the cells resuspended in fresh medium for one or more additional incu-
bations. Supernatants, after centrifugation at 2000g for 20 min, were stored at 40C
for 1-7 days, or at -18°C for 1-3 weeks, before injection.
Reagents
Pronase, B grade (Calbiochem, Los Angeles, California), was prepared for in-
cubation with pyrogen-containing supernatants as described previously (4). Puro-
mycin dihydrochloride 1 X 10-5 M, and Acti-Dione (cycloheximide) 2 X 10-5 M,
(Nutritional Biochemicals Corp., Cleveland, Ohio) were added to lymph node and
spleen cell suspensions in some experiments. Puromycin 5 X 10-5 M was shown to
be inactive in the presence of frozen-thawed spleen tissue; cycloheximide was there-
fore substituted in all later experiments with spleen cells.
Clincal Data
All patients with Hodgkin's disease had unequivocal tissue diagnoses on biopsy.
Diagnoses of other patients had been established by standard criteria. Chart review
was used to obtain relevant clinical data for all patients. A reliable history, or
documentation in hospital, of persistent unexplained fever within one month before
operation was considered evidence for classification of the patient's disease as
febrile.
Statistical Evaluation
Determination of significant differences was made using chi-square and Student's
t test for small samples (9).
RESULTS
Blood Leucocytes
Studies were first made to determine whether blood leucocytes from patients
with Hodgkin's disease produced pyrogen when the patients were febrile. Blood
was obtained from 15 patients with Hodgkin's disease, 6 of whom were febrile.
Blood was also obtained from febrile and afebrile patients with other diseases, in-
cluding infections, leukemia, carcinoma, familial mediterranean fever, and drug
reactions. All febrile patients had temperatures over 100OF at the time blood was
drawn, and in most instances, the temperature was rising. Leucocytes were incu-
bated overnight, and each supernatant was assayed for pyrogen in two or three
rabbits. As shown in Table 1, circulating leucocytes from febrile donors never spon-
TABLE 1
PYItOGEN RELEASE BY BLOOD T,l"l COCYTES itl vitro
Non-
IIo(lgkin's lynliphonla hlealthy
(lisease (lisease Subjects
Febrile doniors 0 /15* 0/19
Afebrile (lonors 2/18 '9/30 3/37
* No. positive responises in rabbits (>0.30C AT)/total.
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TABLE ~
PY1o0GEN RE:LEAFSE BY SPLEEN (CELs ttt vitro
Incubations
0-24 lhr 24-48 lhr + Staph (0-924 hr)
Average saimple- No. No. No.
-. I)ositi-eb positive/ positive'
g. 'BCXIOs ' 1PMN total AT(5C)' total AT((C) total AT(5C)
Hodgkin's 1.08 *2.7 18.-2 11010 136 + 03 160( .56 + .04 90 '90 84 ± .04
(lisease + 1 t; (5-2 .03)d ((60 + 04)
Nonmalignant 1.11 9.8 19. 7 9717 90 ± 03 8 '15 .45 + 05 16 16 75 + 07.
diseases +1.) (.(0±.0 4)
P= <.01 P= <.001 P= <.05
a Suspension from whichl supernatant was (lerive(l per rabbit dose.
b Ntinbers of spleens giving average AT > 0. 13%.
Average AT + SEMN1 of all supernatants.assayed in 31(-89 rabbits.
d Average AT ± SEMI of positive (b') supernatants, assaye(l in 18-44 rabbits.
taneously released pyrogen during in vitro incubations. As shown in the lower half
of the table, blood cells obtained from afebrile patients with Hodgkin's disease,
other diseases, or from healthy donors, also rarely released pyrogen. All prepara-
tions tested except one were capable of pyrogen release when heat-killed staphy-
lococci were added to provide a phagocytic stimulus (not shown). These studies
indicate that circulating leucocytes obtained from febrile patients with Hodgkin's
disease, or other disorders, do not spontaneously release pyrogen in vitro.
Spleen Cells
In order to look for pyrogen production by tissue cells of patients with Hodg-
kins's disease, portions of spleens were obtained at the time of splenectomy from
20 patients with biopsy-proven Hodgkin's disease, and from 17 patients with non-
malignant diseases. The diagnoses in this latter group included idiopathic thrombo-
cytopenic purpura (6 cases), hereditary spherocytosis (4 cases), cirrhosis (2 cases),
and one case each of splenic artery aneurysm, thalassemia, traumatic rupture,
thrombotic thrombocytopenic purpura, and lupus erythematosus. Spleen cells were
suspended for successive 24-hour incubations, as described in methods, and pyrogen
release determined. The results of these studies are presented in Table 2. Significant
release of pyrogen occurred spontaneously during the first 24 hr of incubation in
11 of 20 preparations of spleen cells from patients with Hodgkin's disease, but
in only 2 of 17 from patients with other diseases. This difference is significant
(p = <.01). During a second incubation, detectable pyrogen was released from
16 of 20 suspensions in the first group, and from 8 of 15 in the second. In almost
all instances, tissues which released pyrogen during a first incubation released even
more during a second incubation. All preparations contained cells which were cap-
able of pyrogen release, since they all released pyrogen when heat-killed staphy-
lococci were added.
In addition to the difference in frequency of spontaneous pyrogen production,
the quantity of pyrogen released by spleen cells in the malignant and nonmalignant
groups was also different. The average fevers in rabbits following injection of super-
natants from all tissues in each of the two groups are shown in separate columns
in Table 2. Larger pyrogenic responses were produced by supernatants from tissues
in the first group; the differences are significant for results of both incubations
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FIG. 1. Pyrogen in incubation supernatants of spleen cell suspensions from two patients.
Average febrile responses in 2 or 4 rabbits after injection at time 0 of supernatants from
incubated spleen cells, obtained from one patient with Hodgkin's disease (Hodgkins) and
one with idiopathic thrombocytopenic purpura (ITP). Each rabbit received supernatant corre-
sponding to the following wet weights and white cell counts of tissue suspension: 1.3 g,
2.7 X 10 (Hodgkins); 1.0 g, 4.0 X 10 (ITP).
(p = <.001, <.05). Average fevers produced by supernatants of "positive" tis-
sues only are also included for some groups in Table 2, as indicated. Pyrogen re-
lease after addition of staphylococci was slightly greater by tissues in the first group.
The type of fever produced by injection of supernatant from successive incuba-
tions of spleen cells, from patients with malignant and nonmalignant disease, is
illustrated in Fig. 1. The shape of the fever curves resembles that previously re-
ported for human, as well as rabbit, leucocyte pyrogen, and does not resemble
a typical response to endotoxin (9). Some rabbits received 12-15 pyrogenic injec-
tions during 5 days, without diminution in their febrile responses, indicating lack
of development of tolerance. The protein nature of the pyrogen was established
by incubation of a portion of spleen cell supernatant with pronase. Pyrogenicity
was abolished, whereas the control portion incubated in Tris buffer alone retained
activity (average AT O.0°C and 0.500C, respectively).
Although the numbers of total cells present in the tissue preparations in each
group appeared comparable, differential counts of each spleen cell suspension were
done to determine the types of cells present. The results of these studies indicated
only small differences between the two groups of tissues in average numbers of
polymorphonuclear leucocytes (see Table 2), or of large mononuclear cells. More-
over, there was no correlation between the numbers of either of these types of
cells with the presence or absence of early, spontaneous pyrogen production in
individual preparations. In Fig. 2, the percent of neutrophils in each spleen suspen-
sion is plotted against the average height of the fever response to supernatant
in that experiment. A similar lack of correlation was observed when numbers of
eosinophils were plotted in the same way. It was not possible to accurately distin-
guish by morphology in these preparations between monocytes, macrophages, and
large cells of the lymphocytic series. In some experiments, heat-killed staphylococci
were added to one portion of spleen cells, and after 2 hr incubation, cover slip
smears of washed cells were examined to identify phagocytic cells. Most neutrophils
contained bacteria, and between 5 and 10% of mononuclear cells.
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FIG. 2. Relation between per cent neutrophils and pyrogen production in spleen cell suspen-
sions. Average height of fevers (AT) in rabbits to injection of supernatant from first incuba-
tions of spleen cell suspensions, plotted against percent neutrophils. Tissues from patients
with Hodgkin's disease and nonmalignant diseases are included.
Experiments were next carried out to determine whether pyrogen production
by spleen cell suspensions was an active metabolic process. Aliquots of three prepa-
rations held at 0OC for 24 hr failed to produce detectable pyrogen, unlike the
aliquots incubated normally. In two other experiments, supernatant was removed
from active spleen cell suspensions after one or two hours of incubation, and the
cells disrupted by 5 cycles of freeze-thawing in dry ice and acetone. Neither super-
natant nor cells contained detectable pyrogen. These results indicate that little or
no pyrogen was present in active form in cells or incubation medium at the start
of the incubation.
To determine whether protein synthesis was essential for pyrogen release by tis-
sue cells, as it is in the case of blood PMN and mononuclear cells (10), cyclohexi-
mide (2 X 10-5 M) was added to some flasks, either during a first or second 24-hr
incubation. Control flasks were incubated as usual without inhibitor. The results
of these experiments are presented in Fig. 3. When cycloheximide was added at the
start of the first incubation, it completely suppressed production of pyrogen by
spontaneously active spleen cell suspensions. When cycloheximide was added during
a second incubation, however, only partial suppression of production by these tis-
sues occurred. Addition of inhibitor at 24 hr to flasks containing initially inactive
cells (Fig. 3, right) effectively prevented late pyrogen release. These results indicate
that initial inhibition of protein synthesis prevents pyrogen production by all spleen
cell suspensions, but that only partial inhibition occurs when the inhibitor is added
after significant pyrogen release has begun.
Attempts were made to correlate the behavior of spleen cell preparations in vitro
with clinical findings in patients with Hodgkin' disease. These results are presented
in Table 3. It is clear that initial spontaneous pyrogen release in vitro did not cor-
relate with fever in vivo. Tissues from some markedly febrile patients released little
or no pyrogen in vitro, whereas tissues from afebrile patients frequently produced
large amounts of pyrogen. Similarly, pathologic infiltrates of Hodgkin's disease in
the spleen were not often associated with spontaneously pyrogen-producing cells.
For example, as shown in Table 3, although 11 spleens from patients with biopsy-
proven Hodgkin's disease at other sites released significant amounts of pyrogen
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PYROGEN PRODUCTION BY SPLEEN CELLS
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FIG. 3. Effect of cycloheximide on pyrogen production by spleen cells. Average height of
fevers (AT) + SEM in rabbits to injection of supernatants from successive incubations of
spleen cells. Cycloheximide was added to samples at 0 or 24 hr, as indicated. Numbers of
rabbits are shown in parentheses. Results of experiments in which pyrogen release (average
AT) during a first incubation was > 0.3 °C are presented on the left, "initially positive;"
others, "initially negative," are on the right.
TABLE 3
SPLEEN CELLS FRIOM PATIENTS WITH IHODGKINS DISEASE,
Ilo(dgkinl's
Disease Inexp)laiiled
I..tial iin tissue fevera Stage"
pyrogen
release + - + - II 111 IX
Positivec
(11) 1 1) 4 7 X 3
Negative
(9) 4 5 3 6 3 6
Present in hospital or by history within onie milonitlh of a(dImission.
Assigned after dianiostic procedures colniplete(l.
Average AT >0.30C (see text).
initially, only one of these spleens contained characteristic infiltrates of the disease
on pathologic examination. Correlations were also not evident with the classification
of type of Hodgkin's disease, age of the patients, or diagnostic or therapeutic proce-
dures preceding operation. An apparent relationship was noted, however, between
spontaneous pyrogen release in vitro and stage of disease. Most spleens from pa-
tients with Stage I or IL disease were initially positive, whereas most from patients
with Stage III or IV disease were initially negative. This was probably not related
to differences in therapy, since only 1 patient of 6 in this latter category had re-
ceived treatment within three years of surgery. Data on the presence or absence
of anergy in the patients with Hodgkin's disease was insufficient for analysis.
Lymph Node Cells
Pyrogen production by lymph node cells, obtained at operation from febrile and
afebrile patients with malignant and nonmalignant diseases, was also examined.
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TABLE' 4
PYROG,EN RELEASE BY LYMniPH NOD1)E CELLS inl. Vitfro
Incubations
0-34 hr 34-48 hr + Stapl
No. No. No.
No. Average w-et positivel/ p)ositive/ positive/
flo(les wt (Mg)a total AT(0C) total A T(oC) total A7(°C)
Ho(lgkin's 10 154 6/"10 .33 + .06 510 .35 + .08 6/7 .5±2 + 05
(lisease (.4:3 ± .07)d (.49. + .12)
Lymphoma, 6 197 1 /5 .3±2 .06 16 .332 + .1 3/5 .41 .05
Metastatic
(arcinonia, 6 161 1,/ti . 26 + 06 -.16 .38 + .06 3/3 .57 + .06
llenigni 6 -2303 0,6 .16 ± .04 '6 .31 + .09 4/5 .48 + .C6
liyperplasia
SuspenisioII froIi which sup)ernatant was (lerived per rabbit dose.
b Number of nodes gixing average AT > 0. 35C.
c Average AT + SEIMI of all supernatants, assayed in 7-16 rabbits.
dAverage AT + SEM of positive (b) supernatants, assaye(l in 7-9 rabbits.
Patients with malignant diseases included 10 with Hodgkin's disease, 6 with other
lymphomas, and 6 with metastatic squamous cell or adenocarcinoma. Lymph nodes
obtained from an additional 6 patients were classified as showing benign hyper-
plasia. Six nodes were paraaortic or perisplenic, one was inguinal, and others were
cervical, supraclavicular, or axillary. Tissue suspensions were prepared and incu-
bated as described in Methods.
The results of these studies are presented in Table 4. Significant pyrogen was
released spontaneously during a first incubation by 6 of 10 lymph node cell prepara-
tions from patients with Hodgkin's disease, 1 of 5 from patients with non-Hodgkin's
lymphomas, and only 1 of 12 preparations from patients with other disorders. The
difference between results with Hodgkin's disease tissues and all others combined
is significant( p = <.01). During a second incubation, pyrogen was released from
about half of lymph node cell suspensions from patients with Hodgkin's disease,
and about one-third of those in the other groups. Only small amounts of pyrogen
were usually released by any of the lymph node suspensions, when tested at this
dosage. Fifteen of 19 of the preparations produced detectable pyrogen when stimu-
lated by addition of heat-killed staphylococci (see Table 4). Differential counts
of free lymph node cells in all experiments showed >95% mononuclear cells,
mostly small lymphocytes.
To investigate the effect of inhibitors of protein synthesis on pyrogen production
by lymph node cells, puromycin was added in some experiments to flasks containing
pyrogen-producing cells. Pyrogen production was either spontaneous or induced
by addition of heat-killed staphylococci; since results of both types of experiments
were the same, they have been combined. As shown in Fig. 4, lymph node cells,
like spleen cells, usually continued to produce pyrogen for 2-3 days. Unlike the
results with cycloheximide and spleen cells, however (see Fig. 3), addition of
puromycin to lymph node cells either during a first or second incubation suppressed
pyrogen release. Cycloheximide was equally effective as an inhibitor for lymph node
cells (not shown). These results suggest that continuing protein synthesis is re-
quired for pyrogen release from lymph node cells in vitro.
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FIG. 4. Effect of puromycin on pyrogen production by lymph node cells. Average height of
fevers (AT) ± SEM in rabbits to injection of supernatants from successive incubations of
lymph node cell suspensions. In all but one experiment, lymph nodes were from patients with
Hodgkin's disease. Puromycin was added at 0 or 24 hr, as indicated. Numbers of rabbits are
shown in parentheses.
Correlations between pyrogen production by lymph node cells in vitro and clini-
cal findings in patients with Hodgkin's disease were inconclusive because of the
small number of tissues examined. All nodes but one (a non-pyrogen-producing
tissue) had evidence of Hodgkin's disease on pathological examination. Four of
6 nodes from patients with unexplained fever produced spontaneous pyrogen in-
vitro, but the amounts of pyrogen were not greater than those produced by tissues
from afebrile patients. No other patients, including those with non-Hodgkin's
lymphomas, were febrile. No correlation was evident between pyrogen release and
site of lymph node biopsy, stage or histologic type of Hodgkin's disease, or prior
treatment or procedures. Lymphangiography preceded operation by 2 days to 2
weeks in 6 cases where intraabdominal nodes were studied; 4 of these (3 with
Hodgkin's disease) produced significant early pyrogen.
DISCUSSION
Although pyrogen release from blood or tissue cells has been postulated in the
etiology of fever associated with certain disease states (10), there is little experi-
mental evidence for this in man. Snell (11) demonstrated a rapidly acting pyrogen
in inflammatory effusions from patients with febrile diseases. The presence of this
material, however, did not correlate with fever in the patient at the time the fluid
was withdrawn. Endogenous pyrogen was present in joint fluids from afebrile pa-
tients with rheumatoid arthritis (12). Recently, extracts from two hypernephromas
have been reported to contain endogenous pyrogen-like activity when tested in rab-
bits, whereas tumor tissue removed from one afebrile patient was not pyrogenic
(13). Sokal and Shimaoka (14) reported a pyrogen of unknown nature in urine
from febrile patients with Hodgkin's disease.
In the studies reported here, blood and lymphoid tissue cells from patients with
Hodgkin's disease, as well as other conditions, were incubated in vitro, and pyrogen
production assayed. Blood leucocytes from all febrile patients failed to release pyro-
gen during in vitro incubations, although they were capable of pyrogen release
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when stimulated by heat-killed bacteria. These findings fail to implicate circulating
blood leucocytes as an important source of endogenous pyrogen during fever.
When tissue cells were examined, however, prolonged "spontaneous" pyrogen
production in vitro was noted by lymphoid tissue cells obtained from patients with
Hodgkin's disease. Spleen and lymph node cells from patients with nonmalignant
diseases produced significantly less pyrogen under the same conditions. The pyro-
gen caused rapid pyrogenic responses in rabbits, did not induce tolerance, and was
inactivated by pronase; thus it resembled endogenous, or leucocyte, pyrogen, and
not endotoxin (10).
The mechanism for the "spontaneous" and continuing production of pyrogen by
these tissues is not clear. By analogy with results of studies of blood and exudate
leucocytes (15-17), an activator, such as a microbial product or antigen, presum-
ably initiates the process of pyrogen synthesis and release from tissue PMN or
mononuclear cells. Spleen cell suspensions contained 6-35% PMN leucocytes, and
variable numbers of large mononuclear cells, many of which were phagocytic. Such
cells, like Kupffer cells, lung macrophages, and blood monocytes (10), are prob-
ably capable of pyrogen production. Active cell metabolism and protein synthesis
was required for initiation of "spontaneous" pyrogen production by these tissues
in vitro, as shown by the absence of pyrogen in cell extracts or supernatants ob-
tained before incubation, after incubation at 40C, or when cycloheximide was added
during the first 24-hr period. Continuing pyrogen release by spleen cell suspensions,
however, was only partially sensitive to inhibition by cycloheximide. Passive release
of intracellular pyrogen, synthesized during a first incubation, could explain this
finding. Alternatively, pyrogen production at this stage might be due mainly to
PMN leucocytes, cells which, once activated, can produce pyrogen for a limited
time in the presence of puromycin or cycloheximide (15, 16). Preliminary results
provide some evidence for both mechanisms.
Pyrogen production by lymph node cells, which were >95% mononuclear, con-
tinued for 48-72 hr, and could be inhibited at any time by puromycin. Mononuclear
tissue cells, of unknown type, were presumably responsible for production of pyro-
gen by these tissues. Recent evidence suggests that blood monocytes, as opposed
to PMN leucocytes, require continuing protein synthesis for pyrogen production
(Bodel, unpublished observations). The low fevers induced by supernatants from
many of the lymph node preparatlons may perhaps be explained by the small
amount of tissue available for study. On the other hand, since lymphocytes and
derived lymphoid cell lines do not make pyrogen, even after stimulation (7), the
numbers of cells capable of pyrogen production in most lymph nodes may be small.
The reasons for the differences in pyrogen production by tissues from patients
with Hodgkin's disease compared to those from patients with nonmalignant diseases
are not clear. Involvement of spleen tissue by the lymphomatous process, as deter-
mined by standard pathologic criteria, was clearly not related to its capacity for
significant, early pyrogen production, since tissue from patients with stage III or
IV disease was often less active than that from patients with apparently localized
disease. Involvement of lymph nodes by Hodgkin's disease, however, appeared
to be related to spontaneous early pyrogen production in vitro.
Eight of 16 patients undergoing splenectomy in the nonmalignant group had
received corticosteroids preoperatively, agents which have antipyretic effects both
in vivo and in vitro (6). However, there is no difference between the results of
incubations of tissues from patients receiving or not receiving steroids when initial
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pyrogen release, total pyrogen release, or release after a phagocytic stimulus is
compared. Lymphangiography, a procedure often followed by fever (18), could
have contributed to the "spontaneous" activity of three nodes in the Hodgkin's
disease group, and the one positive node in the lymphoma group. However, nodes
from two other patients subjected to lymphangiography were not active.
Recent theories (19, 20) have postulated that in Hodgkin's disease altered lym-
phocytes act as an autoimmune stimulus to normal lymphoid tissue cells, producing
a kind of graft vs host reaction, with ensuing lymphoid hyperplasia, immunological
deficiency, and eventual neoplastic transformation. After stimulation of sensitized
rabbit lymphocytes by antigen, pyrogen release is induced from blood leucocytes,
perhaps by the action of a lymphokine (21); this mechanism may explain certain
experimental fevers of hypersensitivity in rabbits. By a similar pathway, tissue
lymphocytes from patients with Hodgkin's disease, altered perhaps by virus or
tumor-associated antigen (22), may induce release of pyrogen from tissue PMN or
mononuclear cells. This interaction in vitro could lead to the observed early
"spontaneous" release of pyrogen from tissue cell suspensions. The decreased
reactivity of tissue from patients with late stage disease may reflect suppression or
deficiency of this immune mechanism.
The failure of the in vitro results to correlate with fever in the patient may per-
haps be due to differences between in vivo and in vitro conditions. Pyrogen release
from tissue cells could be enhanced or suppressed in vivo, depending on several
variables, including opportunities for cell activation and presence of factors modi-
fying pyrogen production, release, or transport. Such variables could play an im-
portant role in determining the occurrence of fever in patients with potentially
febrile conditions such as Hodgkin's disease.
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